Related Experiment Video

Updated: Mar 9, 2026

Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation
08:10

Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation

Published on: July 20, 2022

2.2K

Biomarker Assays for Personalised Stroke Risk Assessment in Atrial Fibrillation

Angela Hall1, Rupert F G Simpson1, Andrew R J Mitchell2

  • 1Department of Cardiology, Jersey General Hospital, Jersey, United Kingdom.

Cardiovascular & Hematological Disorders Drug Targets
|January 7, 2017
PubMed

Insights

For atrial fibrillation patients at intermediate stroke risk, cardiac biomarkers like troponin and BNP can improve personalized risk assessment. These markers aid in deciding whether to start anticoagulation therapy.

Area of Science:

  • Cardiology
  • Neurology
  • Biomarker Research

Background:

  • Atrial fibrillation is a significant stroke risk factor.
  • Current guidelines lack consensus on anticoagulation for intermediate-risk patients (CHA2DS2-VASc score 1).
  • Need for enhanced stroke risk stratification beyond conventional tools.

Purpose of the Study:

  • To explore the use of cardiac biomarkers for personalized thromboembolism risk assessment in atrial fibrillation.
  • To aid clinicians in managing intermediate-risk atrial fibrillation patients.
  • To assist in the decision-making process for initiating anticoagulation.

Main Methods:

  • Utilizing advanced cardiac biomarkers: highly sensitive troponins, B-type natriuretic peptide (BNP), and D-dimers.
  • Integrating biomarker data with conventional stroke risk stratification tools.
  • Focusing on patients with atrial fibrillation and an intermediate stroke risk score.

Main Results:

  • Cardiac biomarkers offer incremental enhancements for personalized risk assessment.
  • These markers provide prognostic data for cardiovascular morbidities.
  • Biomarkers add specificity to assessing stroke and thromboembolic risk in atrial fibrillation.

Conclusions:

  • Cardiac biomarkers can improve stroke risk assessment in intermediate-risk atrial fibrillation patients.
  • Personalized risk assessment using biomarkers aids anticoagulation decisions.
  • Biomarker assays enhance risk prognosis alongside existing tools.
Abstract

Keywords:
Atrial fibrillationBNPD-dimersbiomarkerspersonalised medicinestroke risktroponin

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.7K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.2K

Related Concept Videos

Dysrhythmias V: Evaluating Dysrhythmias01:30

Dysrhythmias V: Evaluating Dysrhythmias

Dysrhythmias, also known as arrhythmias, are disturbances in the heart's rhythm that range from benign to life-threatening. A thorough evaluation is crucial for appropriate management and involves a comprehensive medical history, physical examination, and various diagnostic tests.Medical HistorySymptoms: Collect detailed information on palpitations, dizziness, syncope, chest pain, and fatigue. Note their onset, frequency, and triggers.Previous Cardiac Issues: Document any history of heart...
429
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
1.0K
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
681